3Benichou C. Criteria of drug-induced liver disorders. Report ofan international consensus meeting. J Hepatol, 1990,11 (2):272-276.
4Russmann S,Kullak-Ublick GA. Current concepts of mecha-nisms in drug-induced hepatotoxicity. Curr Med Chem,2009,16(23):3041-3053.
5Roeder E. Medicinal plants in China containing pyrrolizidinealkaloids. Pharmazie,2000,55( 10):711 -726.
6Chou MW,Fu PP. Formation of DHP-derived DNA adducts invivo fn)m dietary supplements and Chinese herbal plant ex-tracts containing carcinogenic pyrrolizidine alkaloids. ToxicolInd Health,2006,22(8): 321-327.
7Lucena MI,Camargo R,Andrade RJ,et al. Comparison of twoclinical scales for causality assessment in hepatotoxicity. Hepa-tology,2001,33( I ):123-130.
8Fontana RJ,Seeff LB,Andrade RJ,et al. Standardization ofnomenclature and causality assessment in drug-induced liverinjury:summary of a clinical research workshop. Hepatology,2010,52: 730-742.
9Russo M W,Galanko JA,Shrestha R,et al. Liver transplanta-tion for acute liver failure from drug induced liver injury inthe United States. Liver Transplant, 2004,10(8):1018-1023.
10Eisenberg S. Hepatic sinusoidal obstruction syndrome in patients undergoing hematopoietic stem cell transplant. OncolNurs Forum,2008,35(3 ):385-397.
